2 min read
Outsourcing in Clinical Trials New England
Meet Veristat at Outsourcing in Clinical Trials New England
Veristat is excited to participate in the 17th Annual...
1 min read
Learn how Veristat’s multidisciplinary team was able to work with the sponsor to solve challenges across numerous areas of this full-service phase II cancer trial. Collaborative efforts led to the sponsor decided not to close the Phase II study upon the recommendation of the Safety Review Committee since the primary endpoint was met and there were no safety concerns.
A clinical-stage biopharmaceutical company approached Veristat in a multi-center, randomized Phase II study of a modified synthetic peptide in patients with exocrine pancreatic cancer. The study aimed to establish the efficacy and safety of combinations of the therapy in patients with stage IV exocrine pancreatic cancer.
In this piece, learn how Veristat’s multidisciplinary team was able to work with the sponsor to solve challenges across numerous areas including:
Meet Veristat. Learn More.
2 min read
Oct 2, 2025 Veristat Events
Veristat is excited to participate in the 17th Annual...
1 min read
Sep 18, 2025 Veristat Events
Veristat is excited to attend BIOSpain 2025, one of Europe’s largest...